Objective-To investigate antiretroviral treatment (ART) interruption in a long-term treatment cohort in South Africa. ART between 2004 and were included in this analysis. Defaulting was defined as having stopped all ART drugs for more than 30 days. Treatment interrupters were patients who defaulted and returned to care during the study, whereas loss to follow-up was defined as defaulting and not returning to care. Kaplan-Meier estimates and Possion regression models were used to analyze rates and determinants of defaulting therapy and of treatment resumption.
Introduction
Access to antiretroviral therapy (ART) has improved substantially in resource-limited settings in Africa, Asia and South America where 90% of people with HIV/AIDS reside. According to World Health Organization (WHO) estimates, more than four million people with HIV/AIDS in low and middle income countries had initiated treatment by the end of 2008. 1 Despite this success, ensuring that patients remain in care over time remains one of the major challenges in resource-limited settings. Much attention has been paid to patient adherence 2 -5 , loss to follow-up, and mortality in ART programs in resource-limited settings. 6 -9 A systematic review of 33 patient cohorts from 13 African countries reported that only between 46 and 85% of patients remained in care at two years. 8 The realization that a substantial proportion of patients reported as lost to follow-up may have died has led to concern that there may be significant biases in program outcome reports of survival. 10 Another potential source of bias is the fact that a proportion of patients may only transiently default, returning to care at a later stage. Such unstructured treatment interruption has been reported to occur in around 20% of patients in industrialized settings. 11 - 14 The proportion of patients who transiently interrupt treatment in resource-limited settings is largely unreported.
Treatment interruptions, planned or otherwise, have been found to increase the risk of opportunistic infection and death 15 -17 , with viral load increase and associated CD4 decline most pronounced in the first two months. 16 , 18 -20 Interruptions raise similar concerns with respect to drug resistance and increased mortality as sub-optimal adherence. 11 , 15 , 21 -23 However, few studies have addressed the issue of unstructured treatment interruptions in resource-limited settings. The aim of this study was to investigate the frequency and risk factors of defaulting treatment and identify factors associated with subsequent return to care in a long-term treatment cohort in South Africa.
Methods

Study site and data collection
The study was based in a peri-urban township in the greater area of Cape Town, with a population of approximately 15,000 people and an estimated adult HIV prevalence of 23% in 2005. 24 The community is served by a single public-sector primary care clinic which provides ART free of charge. Initial evaluation for ART eligibility included medical history, physical examination and CD4 cell count. A follow-up appointment was scheduled one to two weeks later when the laboratory results were reviewed and ART eligibility was determined. Patients eligible for ART underwent three adherence counseling sessions before starting treatment.
The initial follow-up schedule for those starting ART included one visit two weeks after ART initiation, followed by monthly visits until month three. Patients who were stable on ART and did not experience any adherence problems were thereafter seen every three months. Three attempts were made to contact patients who had missed appointments.
All patients aged ≥15 years accessing ART in the primary health care clinic between 01 March 2004 and 31 December 2009 were included in the analysis.
Sociodemographic and clinical data at baseline and laboratory data were collected prospectively using a standardized data form. All laboratory tests were performed by the National Health Laboratory Services in Cape Town.
Definitions
Patients defaulting treatment were defined as those who had not presented at the pharmacy for ART refills for more than 30 days. This category included patients who subsequently returned to care and restarted ART (treatment interrupters) and patients who had not returned to care at the time of censoring (loss to follow-up) (figure 1).
Treatment interruption was defined as a patient-initiated episode of more than 30 days of stopping ART (same definition as defaulting) but who subsequently resumed treatment (figure 1).
Patients lost to follow-up were those who stopped ART for more than 30 days and had not returned to care at the time of censoring (figure 1).
Study design
In-programme data on death, transfers outs and loss to follow-up were collected prospectively. Death on ART was defined as any death within three months of drug refill. If the exact date of death was not recorded it was estimated to be the 15 th of the month following the last clinic appointment.
Patients who had stopped ART for more than 30 days and resumed therapy were identified using the pharmacy dispensing data. The electronic pharmacy dispensing system records each time medication is dispensed to a patient. Treatment interruption was verified through folder reviews.
The first endpoint was the time from ART initiation to the first time at which all drugs were stopped for a period of at least 30 days (default). Follow-up of patients on continuous therapy was censored at the date of death, date of transfer, or study end (31 December 2009).
The second endpoint was treatment resumption, defined as the time from defaulting treatment for the first time to the time of restarting ART. Follow-up of patients for whom therapy was not resumed was censored at the date of death, date of transfer, date of migration, or study end. For a proportion of these patients (48%) vital status, date of death, date of transfer and date of migration was determined by home visits.
Statistical analysis
All analyses were carried out using Stata version 10.0 (Stata Corp. LP, College Station, TX, United States of America). Frequency tables were produced for all categorical baseline characteristics. For continuous baseline characteristics the median and interquartile ranges were reported. Standard survival analysis methods, including Kaplan-Meier estimates and Poisson regression models were used to analyze the rate and determinants of defaulting therapy and of treatment resumption after defaulting treatment for the first time. The proportional hazards assumption for potential interaction between each variable and time was tested using the likelihood ratio test. A univariate Poisson regression model was used to determine risk for time-to-event outcomes for each exposure variable. Multivariate models were built through backwards elimination. Sensitivity analyses were conducted excluding individuals with unascertained vital status. All reported p values are exact and 2-tailed, and for each analysis p<0.05 was considered significant.
Ethical approval
The study was approved by the University of Cape Town Ethics Committee and the London School of Hygiene and Tropical Medicine Ethics Committee. Written informed consent was obtained from all patients at enrolment.
Results
Patient characteristics
A total of 1154 patients were included in the analysis (table 1) A total of 291 patients defaulted treatment at least once (figure 1). Among these, 96 resumed therapy (treatment interruption) while 195 did not resume therapy during follow-up (lost to follow-up). Of the 96 individuals resuming therapy, 75 individuals had one episode of treatment interruption, 19 had two and 2 had three. The median time patients failed to receive ART was 228 days (IQR: 126-409) during the first episode of treatment default and 194 days (IQR 121-278) during the second episode. Thirty five patients who had stopped treatment underwent re-screening that included clinical assessment, laboratory tests and adherence counseling and yet did not resume therapy during the period of the study.
Subsequent analyses investigated first episode of treatment interruption by analyzing the time to stopping treatment for the first time and resuming therapy thereafter (non-shaded cells in figure 1 ).
Factors associated with the probability of defaulting treatment
The overall rate of treatment default for the first time was 12.8/100 person years (PYs) (95% CI 11.4-14.4). The Kaplan-Meier estimate of the probability of defaulting treatment for at least 30 days was 14.9% (95% CI 12.7-17.4) by 1 year, 25.6% (95% CI 22.7-28.8) by 2 years and 41.0% (95% CI 37.0-45.3) by 5 years from ART initiation (figure 2).
Factors associated with increased risk of defaulting therapy in univariate analysis were male gender, higher baseline CD4 count, recency of ART initiation and shorter duration on ART (table 2) . Defaulting rate was highest in the first six months of ART (18.2/100 PYs, 95% CI 14.7-22.5) but decreased thereafter and had more than halved after two years (8.8/100 PYs, 95% CI 7.0-11.0).
Gender, baseline CD4 count, time on ART, and date of initiation remained significantly associated with defaulting in the multivariate model. Men were 1.51 (95% CI 1.18-1.93) times more likely to default treatment compared to women, as were those patients with a higher baseline CD4 count. The adjusted hazard of defaulting treatment increased by 1.30 (95% CI 1.17-1.44) for each calendar year. Patients on treatment for more than 2 years had a lower hazard of 0.69 (95% CI 0.48-0.98) of defaulting compared to patients during the first 6 months of treatment. Similar results were found in a sensitivity analysis that excluded individuals whose vital status could not be ascertained.
Factors associated with the probability of resuming therapy
A total of 291 patients defaulted treatment at least once. The overall rate of treatment resumption after defaulting treatment for the first time was 21.4/100 PYs (95% CI 17.5-26.2) (figure 3). The Kaplan-Meier cumulative estimate of the probability of treatment resumption was 26.7% (95% CI 21.7-32.7) in the first year, 37.1% (95% CI 31.1-43.9) in the second year and 42.1% (95% CI 35.2-49.7%) in the third year after stopping treatment.
In univariate analysis a greater likelihood of resuming ART was associated with older age and shorter time since defaulting (table 3) ; gender, residency, calendar year of defaulting and CD4 count nearest to the time of defaulting was not associated with resuming treatment.
In multivariate analysis men were less likely to resume treatment compared to women (IRR 0.67, 95% CI 0.43-1.04, p=0.07); whereas patients >30 years old were more likely to restart treatment (IRR 1.80, 95% CI 1.13-2.89). The likelihood of resuming treatment decreased significantly beyond one year of defaulting treatment (IRR 0.40, 95% CI 0.25-0.63).
Of the 96 patients resuming therapy, 86 had a CD4 count measurement while receiving therapy and before the treatment interruption; the majority of these (80) responded to ART with an increase in CD4. Patients who resumed therapy were found to have a median CD4 count (150.5 cells/μl, IQR: 73-266) comparable to their baseline CD4 count prior to initiating therapy (138.5 cells/μl, IQR: 73-188). The median time between the measurement of CD4 count and resuming therapy was 13 days (IQR 0-28 days).
Excluding individuals with unascertained vital status revealed similar results with regards to parameter estimates, but the association with male gender became non-significant (HR 0.81, 95% CI 0.52-1.26, p=0.35).
Discussion
To our knowledge, this is the first study from sub-Saharan Africa to report on unstructured treatment interruptions in a routine programme setting. Our analysis shows that treatment interruption is a common phenomenon. The probability of ART defaulters to resume therapy within 3 years was 42%. Most ART cohorts report on loss to follow-up defined as not attending the clinic for more than 3 months, 8 and assume that loss to follow-up is an irreversible event. Our study shows that patients who fulfil the widely used definition of loss to follow-up at one time point might resume therapy later. In this cohort, the median duration of the first treatment interruption was 7.5 months.
The median CD4 count of those resuming therapy was similar to their initial CD4 count prior to starting treatment, which underscores the potentially negative impact of interruption leading to a reversal in immunological recovery made while on treatment. Data from industrialised settings suggest that treatment interruption has detrimental effects on CD4 count, viral load suppression, and clinical progression. 11 , 12 , 19 Programmes that report patient attrition and the number of patients in care will not account for the potential that up to 14% of patients in care have interrupted treatment at least once.
We were able to determine risk factors for defaulting ART and factors associated with resuming therapy. Male gender, high baseline CD4 count, recency of ART initiation and the first 6 months of treatment were associated with a higher risk of defaulting. Treatment resumption was more likely in women, patients more than 30 years old and within the first year of stopping therapy.
Our finding that men were at higher risk of defaulting treatment and less likely to resume treatment is consistent with studies showing that HIV-infected men are less likely to access treatment 25 , 26 , have an increased risk for loss to follow-up in the pre-treatment period 27 , present with more advanced stages of HIV disease 28 and have a higher mortality risk on ART. 2 , 9 , 29 -33 Strategies to diagnose HIV in men earlier and to link and to retain them in care might include: i) extending clinic hours into evenings and weekends, ii) training male health care staff and counsellors, iii) offering additional adherence sessions to men and iv) initiating male support groups.
Individuals initiating treatment in more recent years were more likely to default, suggesting that programmatic factors might influence retention in care. A study including data from 15 treatment cohorts from Africa, Asia and South America showed that early patient losses were increasingly common when programs were scaled up. 6 Increasing cohort size in an environment of scarce human resources for health has been suggested to influence both the scale-up capacity and the long-term retention in ART programs. 34 In the study clinic resources and staffing were further reduced when enrolment for the NIH-funded study finished in 2007. In contrast, year of defaulting was not associated with resumption of treatment, suggesting that patient tracing was less influenced by cohort size (although this would vary according to tracing procedures).
Treatment defaulting was more likely in patients with less advanced immunodeficiency at baseline. This may be explained by the fact that individuals who default treatment and stay alive do so because they feel better on treatment, a phenomenon that has been reported by other studies. 35 This finding is particularly important in view of the 2009 WHO guidelines recommending ART initiation at CD4 counts below 350 cells/ μl 36 and when considering initiation of ART regardless of CD4 count as proposed in the 'test and treat' strategy. 37 Initiating ART at the time of HIV diagnosis will result in increased numbers of relatively immunocompetent individuals on ART who may have a higher risk of defaulting treatment. Specific interventions aimed at these individuals need to be developed to ensure optimal retention in care.
This study has several limitations. First, ascertainment of vital status for treatment defaulters was incomplete, which may have led to a misclassification of deaths as defaulters. However, sensitivity analysis excluding individuals with unascertained vital status did not influence our overall findings. Second, resumption of therapy was not ascertained in patients who moved to other communities, possibly resulting in underestimation of treatment resumption. Third, the clinical and immunological consequences of treatment interruption were not analysed due to lack of laboratory data, in particular the lack of capacity to perform routine viral load, and the small number of individuals resuming therapy. However it has been shown in industrialised settings that treatment interruption impacts negatively on CD4 count, viral load suppression and clinical progression. 11 , 12 , 19 We consider that the main finding of this study that a considerable proportion of treatment defaulters return to care is likely to be generalisable to similar settings. Nevertheless, risk factors for defaulting and resuming therapy might differ with regards to eligibility criteria and resources available for patient tracing.
A strength of this study is that the relatively large sample size and follow up time. This allows for an assessment of risk factors for defaulting and treatment interruption that in turn allows for several proposals to be made to limit defaulting and treatment interruption in similar programme settings. In particular, interventions to keep patients in care should be targeted at men, patients with higher CD4 counts and during the first 6 months of ART. Moreover, the finding that the probability of resuming therapy was highest in the first year following treatment defaulting suggests that efforts to bring patients back into care might be most successful early into defaulting treatment. Table 3 Risk factors for resuming treatment after defaulting 
